Scholarlink

Introduction <p>This study aimed to assess knowledge gaps, perceptions, and prescribing approaches of healthcare professionals (HCPs) in Saudi Arabia regarding pain management, particularly neuropathic pain, in the context of recent reclassification of gabapentinoids.</p> Methods <p>A three-lecture webinar was attended by 4922 HCPs across Saudi Arabia. Two structured surveys were embedded within the lectures: a 9-item knowledge questionnaire on pain management and a 10-item questionnaire on HCPs’ opinions and attitudes on gabapentinoid use and prescribing challenges. Responses were recorded on the platform’s interactive dashboard as percentage. The knowledge scores were normalized to percentage.</p> Results <p>Overall knowledge levels varied across specialties with internal medicine (68.7%) and pain specialists (68.3%) having the top scores; non-pain organ specialists scored the lowest (59.1%). The majority of HCPs (68.8%) agreed that prescribing gabapentinoids has become more challenging than prescribing tramadol post reclassification, with patients’ concerns related to substance dependence (32.6%) and extended process in obtaining medication (27.9%) cited by the majority. Gabapentinoids remained the preferred treatment for diabetic peripheral neuropathy by most HCPs (36.8%). Most HCPs (47.4%) reported initiating gabapentinoids at the lowest possible dose and increasing as needed, while a smaller proportion preferred initiating an appropriate dose with minimal adjustments (18.5%). Among pain specialists, these approaches were nearly evenly divided (37.7% and 31.9%, respectively). The majority (45.7%) selected pregabalin 300&#xa0;mg as their preferred daily dose for transitioning from gabapentin 900&#xa0;mg.</p> Conclusions <p>This nationwide survey highlights substantial variability and knowledge gaps related to general pain, neuropathic pain management, and excessive caution among HCPs regarding prescribing gabapentinoids and patient concerns of developing dependence. To maintain gabapentinoid access and timely care for patients with legitimate needs, there is a need to implement educational programs for HCPs across specialties and develop a unified treatment approach that fulfils the guidelines and addresses exaggerated patient worries along with patient-focused initiatives to reduce hesitancy post reclassification of gabapentinoids.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

How the Reclassification of Gabapentinoids Reshaped Neuropathic Pain Treatment in Saudi Arabia: A Survey of Healthcare Professionals

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Abdullah Kaki,
  • Yousef Hamdy,
  • Ashraf Amir

摘要

Introduction

This study aimed to assess knowledge gaps, perceptions, and prescribing approaches of healthcare professionals (HCPs) in Saudi Arabia regarding pain management, particularly neuropathic pain, in the context of recent reclassification of gabapentinoids.

Methods

A three-lecture webinar was attended by 4922 HCPs across Saudi Arabia. Two structured surveys were embedded within the lectures: a 9-item knowledge questionnaire on pain management and a 10-item questionnaire on HCPs’ opinions and attitudes on gabapentinoid use and prescribing challenges. Responses were recorded on the platform’s interactive dashboard as percentage. The knowledge scores were normalized to percentage.

Results

Overall knowledge levels varied across specialties with internal medicine (68.7%) and pain specialists (68.3%) having the top scores; non-pain organ specialists scored the lowest (59.1%). The majority of HCPs (68.8%) agreed that prescribing gabapentinoids has become more challenging than prescribing tramadol post reclassification, with patients’ concerns related to substance dependence (32.6%) and extended process in obtaining medication (27.9%) cited by the majority. Gabapentinoids remained the preferred treatment for diabetic peripheral neuropathy by most HCPs (36.8%). Most HCPs (47.4%) reported initiating gabapentinoids at the lowest possible dose and increasing as needed, while a smaller proportion preferred initiating an appropriate dose with minimal adjustments (18.5%). Among pain specialists, these approaches were nearly evenly divided (37.7% and 31.9%, respectively). The majority (45.7%) selected pregabalin 300 mg as their preferred daily dose for transitioning from gabapentin 900 mg.

Conclusions

This nationwide survey highlights substantial variability and knowledge gaps related to general pain, neuropathic pain management, and excessive caution among HCPs regarding prescribing gabapentinoids and patient concerns of developing dependence. To maintain gabapentinoid access and timely care for patients with legitimate needs, there is a need to implement educational programs for HCPs across specialties and develop a unified treatment approach that fulfils the guidelines and addresses exaggerated patient worries along with patient-focused initiatives to reduce hesitancy post reclassification of gabapentinoids.